ABBOTT INDIA LIMITED

FDA clears Abbott's FreeStyle Libre 2 and 3 CGMs for use during X-rays, CT scans, and MRIs, making them the first patient-applied CGMs approved for such procedures.

Beta Bionics integrates iLet bionic pancreas with Abbott's FreeStyle Libre 3 Plus, making it the first U.S. automated insulin delivery system to do so. The iLet system, which received FDA clearance in 2023, simplifies diabetes management by requiring only the user's weight, eliminating carb counting and manual insulin adjustments. Abbott's Libre 3 Plus CGM provides minute-by-minute readings to aid in insulin dose calculations.

DelveInsight's 'Epilepsy Pipeline Insight, 2024' report details 75+ companies developing 90+ therapies, including RLS103, CT-010, EQU 001, and others, with insights on mechanism of action, route of administration, and clinical trials. Key companies include Novartis, Pfizer, Sanofi, and Takeda, among others.

Medtronic received FDA approval for its Affera mapping and ablation system for treating persistent atrial fibrillation (AFib). Affera combines mapping technology with a catheter capable of radiofrequency (RF) and pulsed field ablation (PFA), distinguishing it from existing PFA-only systems like Medtronic’s Pulseselect and Boston Scientific’s Farapulse. Analysts view Affera as a significant upgrade, potentially shifting physician preference from 100% Farapulse to a mix including Affera and Johnson & Johnson’s Varipulse. The approval positions Affera to compete with Abbott and J&J in RF ablation, with potential market impact expected to ramp up by fiscal 2026.

Abbott launches TEAM-HF trial to identify heart failure patients suitable for early HeartMate 3 LVAD therapy, aiming to improve survival rates and quality of life by remotely monitoring pulmonary artery pressures.

Abbott launches TEAM-HF trial to improve heart failure outcomes using CardioMEMS HF system and HeartMate 3 LVAD, aiming to identify high-risk patients earlier for LVAD intervention.

Abbott launches TEAM-HF trial to improve heart failure outcomes using AI and CardioMEMS™ HF System, aiming to identify patients needing early intervention with HeartMate 3™ LVAD.

The Biotechnology Reagents Market is projected to grow at a CAGR of 7.98%, reaching $173.87 Bn by 2030. North America leads due to high investments and strong healthcare infrastructure. Market drivers include rising R&D investments and new techniques, while restraints are high costs and stringent regulations.